-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J3DhX5m/PRDBrj0m5Mt4Dshq151A0yqB+EI5ZnniBmrxazDT54NwUgHDNCfzqL6V j69zSU+7QHx8//z+PHSxVQ== 0000950123-09-038212.txt : 20090826 0000950123-09-038212.hdr.sgml : 20090826 20090826161527 ACCESSION NUMBER: 0000950123-09-038212 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090819 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20090826 DATE AS OF CHANGE: 20090826 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALKERMES INC CENTRAL INDEX KEY: 0000874663 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232472830 STATE OF INCORPORATION: PA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14131 FILM NUMBER: 091036563 BUSINESS ADDRESS: STREET 1: 88 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139-4136 BUSINESS PHONE: 617-494-0171 8-K 1 b77018e8vk.htm FORM 8-K FORM 8-K
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 19, 2009
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)
         
PENNSYLVANIA   1-14131   23-2472830
(State or Other Jurisdiction of Incorporation)   (Commission
File Number) 		  (I.R.S. Employer
Identification No.)
         
88 Sidney Street
Cambridge, Massachusetts
(Address of principal executive offices) 		      02139
(Zip Code)
         
Registrant’s telephone number, including area code: (617) 494-0171
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 7.01 Regulation FD Disclosure
          Alkermes, Inc. (“Alkermes”) has received notification from Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (collectively “Janssen”), that based on a portfolio review it has decided not to pursue further development of the four-week long-acting injectable formulation of risperidone.
          Janssen continues to commercialize RISPERDAL® CONSTA® (risperidone) Long-Acting Injection in over 60 countries worldwide. RISPERDAL CONSTA is based on Alkermes’ Medisorb® technology and is manufactured by Alkermes. It is the first and only long-acting atypical antipsychotic therapy available for both the treatment of schizophrenia and bipolar I disorder.

 

 

SIGNATURE
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  ALKERMES, INC.
 		  
Date: August 26, 2009  By:   /s/ James M. Frates    
    James M. Frates   
    Senior Vice President, Chief Financial Officer and
Treasurer 		  

3

-----END PRIVACY-ENHANCED MESSAGE-----